ISAL 2019 | Hellstrand lab leukemia research: exploring immune escape and defining therapeutic targets

Kristoffer Hellstrand

Kristoffer Hellstrand, MD, PhD, discusses his group’s aims and ongoing work at Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden, which includes both basic research and the clinical development of agents. Prof. Hellstrand also discusses a recent publication from his group on how HLA-B-21 dimorphism impacts NK-cell function and the clinical outcome of immunotherapy in acute myeloid leukemia (AML).

Share this video